This is an important question and one that we are thankfully much more likely to have to address than ever before. I think that slightly more contemporary iterations of this question can be asked for a patient with a Her2 positive, PD-L1 CPS >1 tumor who has received pembrolizumab/trastuzumab an...

This is a good question and I think it comes down to patient and oncologist preference. I would probably keep going as long as the heart function is normal and no other serious adverse effects of the Herceptin exist. I do not think it is wrong to stop and carefully watch either. If we look at the br...